¿Qué pasa cuando nos encandilamos con el tronco y no vemos el resto de las lesiones?

What Happens When We Are Blinded by Left Main Disease and Ignore All Other Lesions?

According to this recent Excel analysis, mortality seems to rise when the SYNTAX II score is not taken into account when defining the revascularization strategy. The difference does not reach statistical significance and further studies are required, but the message is clear: the left main coronary artery is not the only thing that matters; other<a href="https://solaci.org/en/2019/06/24/what-happens-when-we-are-blinded-by-left-main-disease-and-ignore-all-other-lesions/" title="Read more" >...</a>

The Most Read Articles of may in Interventional Cardiology

1- Surprising EXCEL Outcomes in Diabetics with Main Left Stenosis This study especially designed to compare PCI vs. CABG in patients with left main coronary artery disease and low to intermediate Syntax score showed that 30-day and 3 -year outcomes of PCI with everolimus eluting stents vs CABG were consistent both in diabetic and non-diabetic<a href="https://solaci.org/en/2019/06/06/the-most-read-articles-of-may-in-interventional-cardiology/" title="Read more" >...</a>

EuroPCR 2019 | EFFPAC: New Peripheral Paclitaxel Coated Balloons, Efficacy with no Sign of Mortality

Paclitaxel coated balloons in peripheral territory have been under the spotlight for alleged increased mortality, which even though not observed in this study, experts insist, calls for new studies with enough statistical power. Compared against plain balloon angioplasty, paclitaxel coated balloons resulted in improved patency and less revascularization at 24 months in superficial or popliteal<a href="https://solaci.org/en/2019/05/29/europcr-2019-effpac-new-peripheral-paclitaxel-coated-balloons-efficacy-with-no-sign-of-mortality/" title="Read more" >...</a>

EuroPCR 2019 | Stent Firehawk continúa con sus buenos resultados a 2 años frente al Xience

EuroPCR 2019 | Stent Firehawk Continues to Show Good Results at 2 Years vs. Xience

This device, an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent manufactured in China, showed very similar efficacy and safety to the “gold standard” everolimus eluting Xience at 2-year follow up, according to the TARGET outcomes, presented yesterday at the EuroPCR 2019 and simultaneously published in J Am Coll Cardiol Intv. The device, which is manufactured in China<a href="https://solaci.org/en/2019/05/27/europcr-2019-stent-firehawk-continues-to-show-good-results-at-2-years-vs-xience/" title="Read more" >...</a>

EuroPCR 2019 | BASKET-SMALL 2: balones farmacológicos vs DES en vasos pequeños

EuroPCR 2019 | BASKET-SMALL 2: Drug-Coated Balloons vs. DES in Small Vessels

This angiographic substudy supports the safety of drug-coated balloons in small vessels. Despite better angiographic outcomes, there were eight cases of stent thrombosis among drug-eluting stent (DES) patients, while there was none with drug-coated balloons. In patients with small vessels, using a drug-coated balloon appears safe and comparable to DES, with favorable angiographic outcomes at<a href="https://solaci.org/en/2019/05/27/europcr-2019-basket-small-2-drug-coated-balloons-vs-des-in-small-vessels/" title="Read more" >...</a>

REVELATION: Balones liberadores de droga en infartos con supradesnivel del segmento ST

EuroPCR 2019 | REVELATION: Drug Coated Balloons in ST Elevation MI

Drug coated balloons in the context of ST elevation acute myocardial infarction seem safe and feasible under certain circumstances. This single center study is the kickoff to keep studying the possibility of “leaving nothing behind” after primary PCI. This small randomized study revives drug coated balloons to be used particularly instead of stents in young<a href="https://solaci.org/en/2019/05/24/europcr-2019-revelation-drug-coated-balloons-in-st-elevation-mi/" title="Read more" >...</a>

The First Antidote Against Ticagrelor Is a Rapid-Acting, Extended Effect Agent in Preliminary Results

This study attempts to test drug PB2452 for use in cases of catastrophic bleeding and, then, its potential use in other scenarios involving patients receiving ticagrelor. This specific ticagrelor reversal agent stops immediately and substantially the effect of the aforementioned P2Y12 receptor antagonist according to several test measurements conducted during this phase 1 trial in<a href="https://solaci.org/en/2019/05/16/the-first-antidote-against-ticagrelor-is-a-rapid-acting-extended-effect-agent-in-preliminary-results/" title="Read more" >...</a>

Oportunidades perdidas en pacientes con enfermedad vascular periférica

Patients: What They Really Want to Know about Their Disease

When we decide that 30-day mortality to repair an abdominal aortic aneurysm (AAA) is at least twice as high with conventional surgery compared against endovascular treatment, many of us think choosing a strategy is far from hard, and recent stats show exactly that. However, are we sure our patient agrees with us, or at least<a href="https://solaci.org/en/2019/05/15/patients-what-they-really-want-to-know-about-their-disease/" title="Read more" >...</a>

¿Qué pacientes con bajo flujo y bajo gradiente se benefician del recambio valvular?

Would TAVR Have a Similar Benefit in Patients with Low Flow, Low Gradient, and Preserved Ejection Fraction?

Courtesy of Dr. Carlos Fava. Patients with low-flow low-gradient severe aortic stenosis are at higher risk, but there is a low-flow low-gradient group with preserved ejection fraction. These patients present systolic and diastolic ventricular dysfunction and their progress is different than that of the high-flow high-gradient normal ventricular function group. This study analyzed 1462 patients. Among them,<a href="https://solaci.org/en/2019/05/07/would-tavr-have-a-similar-benefit-in-patients-with-low-flow-low-gradient-and-preserved-ejection-fraction/" title="Read more" >...</a>

SOLACI-SIAC-SDC-Virginia University Joint Session

Join us on May 15 thru 18 in Punta Cana, Dominican Republic, to celebrate the 27th Inter-American Congress and the 27th Dominican Congress of Cardiology, organized by the Inter-American Society of Cardiology (SIAC), where SOLACI will proudly hold a joint scientific session with the Inter-American Society of Cardiology (SIAC), the Dominican Society of Cardiology (SCD)<a href="https://solaci.org/en/2019/05/07/solaci-siac-sdc-virginia-university-joint-session/" title="Read more" >...</a>